Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Cash from Financing Activities (2018 - 2025)

Neurogene's Cash from Financing Activities history spans 6 years, with the latest figure at $20.7 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 89.13% year-over-year to $20.7 million; the TTM value through Dec 2025 reached $30.4 million, down 83.47%, while the annual FY2025 figure was $30.4 million, 83.47% down from the prior year.
  • Cash from Financing Activities reached $20.7 million in Q4 2025 per NGNE's latest filing, up from $9.7 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $190.1 million in Q4 2024 to a low of -$6.5 million in Q1 2024.
  • Average Cash from Financing Activities over 3 years is $25.6 million, with a median of $119000.0 recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: tumbled 6197.2% in 2024, then skyrocketed 7312.21% in 2025.
  • A 3-year view of Cash from Financing Activities shows it stood at $94.3 million in 2023, then surged by 101.56% to $190.1 million in 2024, then plummeted by 89.13% to $20.7 million in 2025.
  • Per Business Quant, the three most recent readings for NGNE's Cash from Financing Activities are $20.7 million (Q4 2025), $9.7 million (Q3 2025), and $54000.0 (Q2 2025).